Stockwatch

Atalaya Mining PLC
Symbol	AYM
Shares Issued	139,856,709
Close 2022-06-22	C$ 5.64
Market Cap	C$ 788,791,839
Recent Sedar Documents

Atalaya grants options to buy 1.22 million shares

2022-06-24 09:31 ET - News Release

News Subject: SEDAR News: Irwin Naturals Inc. (formerly Datinvest International Ltd.) PDF Document File: Attachment 03546671-00000001-00005926-C@#Upload#IrwinNaturals#2023#Jun1#Irwin_PR_0531-PDF.pdf May 31, 2023 Irwin Naturals Reports Q1 2023 Financial Results LOS ANGELES, May 31, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) ("Irwin" or the "Company") today reported its financial results for the first quarter and year ended March 31, 2023, on www.sedar.com. Financial Highlights for Q1 2023 (all comparisons are for the year ended December 31 unless otherwise indicated): Q1 2023 revenue was $22.5 million, down 0.4% from $22.6 million in Q1 2022. Income from operations decreased $4.0 million from $2.5 million in Q1 2022 to a loss of $1.5 million in Q1 2023. The decrease is primarily attributed to the continued startup costs related to the Company's 2022 and 2023 Acquisitions at Irwin Naturals Emergence (the company acquired 13 mental health clinics and one advertising platform) and Irwin Naturals Cannabis (intellectual property licensing to the cannabis industry). Q1 2023 net loss of $7.7 million includes $6.5 million of impairment charges related to the 2022 Acquisitions. Financial Highlights for Q1 2023 and Year to Date 2023 Secured a credit facility as of February 1, 2023 with its existing commercial lender for $40 million, with the potential of being up to $60 million. Completed the acquisition of Serenity Health, LLC, one of the leading ketamine clinics in Louisville, KY on February 17, 2023. Announced the successful acquisition of Keta Media, LLC, dba Ketamine Media, the nation's foremost advertising company dedicated to raising awareness about the clinical use of ketamine, on March 17, 2023. Operational Highlights Irwin Naturals has commenced its expansion into the high-growth cannabis and psychedelics sectors. During the first quarter of 2023, the Company launched the first products to the continental cannabis market and has signed ten brand licensing deals that will see Irwin Naturals products enhanced with THC be offered in places like California, Colorado, Mississippi, Michigan, New Mexico, Oregon, Oklahoma, and Canada. Additionally, to date, the Company has announced the acquisition of thirteen clinics and one advertising company specializing in ketamine clinics. The Company will continue to build upon this solid foundation and make the necessary investments to support our growth objectives within the psychedelics sector. Sean Sand, CFO, stated, "During the first quarter of 2023, we launched the first products related to our licensing in our cannabis sectors. We expanded our mental health clinics footprint in Kentucky through an acquisition and acquired an advertising platform to expand our customer outreach at our mental health clinics." About Irwin Naturals Irwin Naturals has been a household name and best-in-class nutraceutical company since 1994. It is now leveraging its brand into both the cannabis and psychedelic sectors. On a mission to heal the world with plant medicine, Irwin has operated its nutraceutical business profitably for over 28 years. The growing portfolio of products is available in more than 100,000 retail doors across North America, where 80% of households know the Irwin Naturals brand. In 2018, the Company first leveraged its brand to expand into the cannabis industry by launching hemp-based CBD products into the mass market. The Company is now leveraging its famous halo of brand trust to become, perhaps, the first household name brand to offer THC-based products. Its rapidly growing national chain of psychedelic mental health clinics is called Irwin Naturals Emergence. For investor-related information about the Company, please visitir.irwinnaturals.com/. To contact the Company's Investor Relations department, please call toll-free at (800) 883- 4851 or send an email to Investors@IrwinNaturals.com. "Klee Irwin" ________________________________ Klee Irwin Chief Executive Officer T: 310-306-3636 investors@irwinnaturals.com Regulatory Overview The following is a brief summary of regulatory matters concerning ketamine in the United States ("US"). Under the Controlled Substances Act (21 U.S.C. paragraph 811) (the "CSA"), ketamine is currently a Schedule III drug as well as being listed under the associated Narcotic Control Regulations, and psilocybin is currently a Schedule I drug. Most US States have enacted Controlled Substances Acts ("State CSAs") which regulate the possession, use, sale, distribution, and manufacture of specified drugs or categories of drugs and establish penalties for State CSA violations and form the basis for much state and local drug laws enforcement activity. State CSAs have either adopted drug schedules identical or similar to the federal CSA schedules or, in some instances, have incorporated the federal scheduling mechanism. Among other requirements, some US States have established a prescription drug monitoring or review programs collect information about prescription and dispensing of controlled substances for the purposes of monitoring, analysis and education. In the United States, facilities holding or administering controlled substances must be registered with the US Drug Enforcement Agency ("DEA") to perform this activity. As such, medical professionals and/or the clinics in which they operate, as applicable, are also required to have a DEA license to obtain and administer ketamine (a "DEA License"). While ketamine is a controlled substance in the United States, it is approved for general anesthetic induction under the US Food, Drug, and Cosmetic Act. Once a drug is approved for use, physicians may prescribe that drug for uses that are not described in the product's labelling or that differ from those tested by the manufacturer and approved by the Food and Drug Administration (the "FDA"). Licensed medical practitioners may prescribe ketamine legally in Canada or the United States where they believe it will be an effective treatment in their professional judgment. Please see Irwin's filing statement on its SEDAR profile for more information on the regulatory environment and regulations surrounding the US THC industry. Forward-Looking Information This news release contains certain forward-looking statements that reflect the current views and/or expectations of management of the Company with respect to performance, business and future events. Forward-looking statements can often be identified by words such as "may", "will", "would", "could", "should", "believes", "estimates", "projects", "potential", "expects", "plans", "intends", "anticipates", "targeted", "continues", "forecasts", "designed", "goal", or the negative of those words or other similar or comparable words. Forward-looking statements are based on the then-current expectations, beliefs, assumptions, estimates and forecasts about the business and the industry and markets in which the Company operates. The Company does not undertake any obligation to release publicly any revisions for updating any voluntary forward-looking statements, except as required by applicable securities law. Neither the CSE nor its Market Regulator (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. SOURCE: Irwin Naturals, Inc. EBITDA and Adjusted EBITDA - Reconciliation The Company defines EBITDA and Adjusted EBITDA as per the table below. It should be noted that these performance measures are not defined under IFRS and may not be comparable to similar measures used by other entities. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows: Three Months Ended March 31 (in thousands) 2023 2022 $ Change % Change Statement of Profit $ (7,698 ) $ 1,581 $ (9,279 ) (100.0 +) Net (loss) income 249 100.0 + Interest expense, net 511 696 262 (100.0 +) Income taxes (recovery) 405 Depreciation and amortization (639 ) (1,335 ) 89.9 2,931 (100.0 +) EBITDA 769 4 364 100.0 + Foreign currency translation adjustments -- (100.0 ) Gain on contingent consideration (7,057 ) -- (9,998 ) 100.0 Intangible assets impairment -- 100.0 Goodwill impairment 18 14 (100.0 +) 2,935 Adjusted EBITDA (390 ) (390 ) 3,739 3,737 2,810 2,810 $ (880 ) $ $ (3,815 ) Irwin Naturals, Inc. March 31, December 31, Consolidated Statements of Financial Position 2023 2022 As of December 31, 2022 and 2021 (Expressed in US Dollars, rounded in thousands except share data) $ 6,529 $ 800 ASSETS 16,347 21,311 Current assets: 21,671 22,506 Cash Trade receivables, net 3,344 2,932 Inventory Prepaid expenses and other current assets 47,891 47,549 Total current assets 353 271 Non-current assets: 4,741 4,194 Property and equipment, net Right-of-use assets 6,935 6,014 Notes receivable from shareholders Notes receivable from related parties 505 255 Goodwill Intangible assets, net 21,190 10,215 Deferred tax asset Other non-current assets 6,160 7,677 Total non-current assets 2,367 2,367 TOTAL ASSETS 277 259 LIABILITIES Current liabilities: 42,528 31,252 Trade and other payables $ 90,419 $ 78,801 Reserve for returns Lease liabilities, current $ 13,747 $ 17,997 Line of credit, net of debt issuance costs 2,036 Notes payable due to acquiree 1,891 1,817 Notes payable, current 1,495 16,448 Total current liabilities -- Non-current liabilities: 26,373 36 Lease liabilities, non-current 5,500 38,334 Notes payable, non-current Contingent consideration 45 2,529 Notes payable due to acquiree Deferred tax liability 49,051 498 6,154 Total non-current liabilities 3,431 TOTAL LIABILTIES -- 656 983 EQUITY AND NONCONTROLLING INTEREST 10,164 Class B Shares, 320,000,000 shares authorized, issued and outstanding 5,764 48,498 Subordinate Voting Shares, 3,389,224 shares authorized, issued and outstanding Multiple Voting Shares, 18,240 shares authorized, issued and outstanding 7,000 13,750 Proportionate Voting Shares, 2,085,200 shares authorized, issued and outstanding 7,068 Warrants reserve 983 59 Accumulated other comprehensive income 5,610 Retained (deficit) earnings 17,834 30 3 Total controlling interest $ 66,885 $ (3,324 ) Noncontrolling interest $ 13,750 $ 23,196 TOTAL EQUITY AND NONCONTROLLING INTERST 7,107 TOTAL LIABILTIES AND EQUITY 7,984 30,303 59 78,801 5,610 30 21 (10,955 ) 16,499 7,035 23,534 $ 90,419 $ Irwin Naturals, Inc. Three Months Ended March 31, Consolidated Statements of Profit and Comprehensive Income For the Years Ended December 31, 2022 and 2021 2023 (Restated) (Expressed in US Dollars, rounded in thousands except share data) 2022 Operating revenue $ 22,506 $ 22,594 Cost of sales Gross profit (11,399 ) (11,548 ) Selling, general and administrative expenses Income (loss) from operations 11,107 11,046 Other (income) expenses: 12,572 8,520 Interest expense (income), net Loss (gain) on foreign currency exchange (1,465 ) 2,526 Goodwill impairment Intangible assets impairment 511 249 Intangible assets amortization 2 Gain on contingent liabilities 2,810 Total other expenses (income) 3,739 Net (loss) income before income taxes 200 Income tax (recovery) expense (390 ) 249 Net (loss) income 6,872 2,277 (8,337 ) Less: net (loss) income attributable to non-controlling interest (639 ) 696 Net (loss) income attributable to controlling interest (7,698 ) 1,581 Comprehensive Income (72 ) 237 Net (loss) income (7,626 ) 1,344 Foreign currency translation adjustments $ (7,698 ) $ 1,581 Total comprehensive (loss) income Less: net (loss) income attributable to non-controlling interest 18 4 1,585 Comprehensive (loss) income attributable to controlling interest (7,680 ) 237 (Loss) earnings per share, controlling interest basic (72 ) 1,348 (Loss) earnings per share, controlling interest diluted Weighted average number of shares outstanding basic $ (7,608 ) $ Weighted average number of shares outstanding diluted $ (2.27 ) $ 1.12 $ (2.27 ) $ 0.00 3,358,211 1,200,001 3,358,211 321,376,574 Irwin Naturals, Inc. Three Months Ended March 31, Consolidated Statements of Cash Flows For the Years Ended December 31, 2022 and 2021 2023 2022 (Expressed US Dollars, rounded in thousands) $ (7,698 ) $ 1,581 Net (loss) income Adjustments to reconcile to net cash (used in) provided by operating activities: 769 405 (390 ) -- Depreciation and amortization 2,810 -- Gain on contingent consideration 3,739 -- Goodwill impairment 59 Intangible assets impairment 80 Change in allowance for doubtful accounts 211 (193 ) Change in inventory reserve 332 Change in deferred tax asset -- Notes receivable from shareholder (900 ) -- Notes receivable from related parties (250 ) (100 ) Interest expense, net Changes to working capital: (18 ) 2 Trade receivables Inventory 6,228 99 Prepaids expenses and other current assets 624 (1,159 ) Trade and other payables (401 ) Reserve for returns 224 Other non-current assets (3,770 ) 2,074 Net cash (used in) provided by operating activities (145 ) (323 ) (3 ) Cash flows from investing activities: 2 Business acquisitions, net of cash acquired 886 Purchases of property and equipment 3,003 Net cash used in investing activities (4,384 ) 105 (15 ) (20 ) Cash flows from financing activities: 85 Proceeds from line of credit (4,399 ) Payments to line of credit Payments to notes payable 35,773 17,497 (25,165 ) (20,035 ) Payments of debt issuance costs Payments on operating leases (124 ) -- Purchase of treasury stock Net cash provided by (used in) financing activities (733 ) -- Effect of foreign exchange on cash Net increase in cash (461 ) (341 ) Cash at beginning of the year Cash at end of the year (66 ) -- 9,224 (2,879 ) 18 19 5,729 228 800 625 $ 6,529 $ 853 Source: Irwin Naturals